Company intelligence / Profile preview

ProfoundBio

Seattle, Washington, United Statesir.genmab.com ↗

Ownership: Private
Development stage: Phase 2

Overview

ProfoundBio developed a pipeline of novel ADCs targeting solid tumors and blood cancers. Its lead program targeted folate receptor alpha for ovarian cancer, with another key asset targeting PTK7 in Phase 1/2 trials for various solid tumors. The company’s proprietary linker technology was highlighted as a differentiator. In May 2024, the company was acquired by Genmab for $1.8 billion. No pivotal or late-phase results were reported prior to acquisition.

Therapeutic areas: Oncology
Modalities: Antibody-drug conjugates (ADCs)antibody-based therapeutics
Industry: Biotech

Drug pipeline

4 assets

rinatabart sesutecan

Phase 2

Indications: Ovarian cancer, Endometrial cancer

3 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on ProfoundBio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ProfoundBio.

Explore the full profile